Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of nivolumab plus temozolomide and radiation in newly diagnosed MGMT-methylated glioblastoma
jRCT2080223128Phase 3Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, single-blind trial in glioblastoma (GBM) comparing Nivolumab + standard chemoradiation with Placebo + standard chemoradiation (2 arms). Started Mar 2016; status: completed.
02
Drugs
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on jRCT2080223128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223128.